Dimethyl Sulfoxide
Apexbio Technology LLC Tasquinimod 254964-60-8 10mM (in 1mL DMSO)
Tasquinimod (CAS 254964-60-8) is an orally bioavailable quinoline-3-carboxamide compound with antiangiogenic and antitumor properties It modulates angiogenesis primarily through dual inhibition of S100A9/TLR4 signaling in myeloid-derived suppressor cells (MDSCs) and downregulation of HIF-1 and VEGF expression in tumor and endothelial cells It also enhances thrombospondin-1 (TSP-1) expression further suppressing neovascularization Preclinical studies in human prostate cancer xenograft models indicate significant antineoplastic activity particularly in combination with docetaxel radiation therapy or androgen-depletion strategies suggesting its therapeutic potential for castration-resistant prostate cancer (CRPC)
Apexbio Technology LLC SU6656 330161-87-0 10mM (in 1mL DMSO)
SU6656 (CAS 330161-87-0) is a selective small-molecule inhibitor targeting Src family tyrosine kinases enzymes involved in pathways promoting cellular survival proliferation angiogenesis and invasion In NIH 3T3 cells SU6656 suppresses PDGF- and Src-induced cell cycle progression and c-Myc expression In UT-7/TPO leukemia cells SU6656 induces cell cycle arrest with increased DNA content and elevates CD41/CD61 surface expression Additionally SU6656 enhances radiation-mediated endothelial apoptosis and vascular disruption by inhibiting Src-dependent Akt phosphorylation suggesting its potential utility in antitumor angiogenesis research
Apexbio Technology LLC Bosutinib (SKI-606)(Synonyms: SKI-606, Bosulif, SKI606, Bosutinib monohydrate), 10mM (in 1mL DMSO), CAS: 380843-75-4.
Bosutinib (SKI-606 CAS 380843-75-4) is a dual inhibitor targeting c-Src and Abl kinases with IC50 values of approximately 1 2 nM and 1 nM respectively It suppresses phosphorylation of Bcr-Abl Src and Stat5 in chronic myeloid leukemia (CML) cells thereby decreasing proliferation and inducing regression in K562 xenograft tumor models Bosutinib also reduces Src autophosphorylation and inhibits -catenin signaling by blocking its interaction with TCF4 transcription factor consequently downregulating cyclin D1 expression in colorectal cancer cells This mechanism results in decreased cell motility and enhanced -catenin binding to E-cadherin highlighting utility in cancer research
TARGETMOL CHEMICALS INC TRAMETINIB DMSO SOLVATE 200MG
Also available in 10 mg 25 mg 50 mg 100 mg 1 mL 10 mM (in DMSO) and bulk. Please contact Fisher for quotes. Trametinib (DMSO solvate) (GSK-1120212 (DMSO solvate)) is a Highly Potent and Selective MEK Inhibitor that specifically inhibits MEK1/2(IC50 2 nM)purity: 99%
Apexbio Technology LLC UMI-77(Synonyms: UMI 77, UMI77, UMI-77 Mcl-1 inhibitor, Mcl-1 inhibitor UMI-77, 518303-20-3), 10mM (in 1mL DMSO), CAS: 518303-20-3.
UMI-77 (CAS 518303-20-3) is a small-molecule inhibitor targeting the anti-apoptotic protein Myeloid cell leukemia-1 (Mcl-1) a member of the Bcl-2 protein family implicated in apoptotic regulation and cell survival signaling Biochemical assays demonstrate that UMI-77 binds selectively to the BH3-binding groove of Mcl-1 protein competing effectively against pro-apoptotic BH3 peptides (Ki 0 49 M) Additionally UMI-77 disrupts the interaction of Mcl-1 with pro-apoptotic factors such as Bax (IC50 1 43 M) promoting apoptosis in cancer cells Preclinical studies on pancreatic cancer cell lines and BxPC-3 xenograft mouse models show that UMI-77 suppresses tumor growth and induces apoptotic cell death highlighting its value as a research tool for studying apoptosis-related oncogenic pathways
Apexbio Technology LLC Matrine(Synonyms: Sophocarpidine, Matridin, (-)-Matrine, α-Matrine, (−)-α-Matrine, L-Matrine, Kushenin), 10mM (in 1mL DMSO), CAS: 519-02-8.
Matrine (CAS 519-02-8) is an alkaloid derived from plants in the Sophora genus with demonstrated anticancer and anti-inflammatory activities It functions in part through agonism of kappa-opioid and possibly other receptors Matrine inhibits the MNK45 gastric cancer cell line proliferation (IC50 540 g/ml MTT assay) by modifying protein expression profiles (e g NF- B XIAP CIAP p-ERK) In vitro matrine induces apoptosis in NSCLC cells through ROS generation caspase activation and p38 pathway modulation Animal studies suggest therapeutic roles in cardiac injury and sepsis-related lung inflammation
Apexbio Technology LLC N6022(Synonyms: N6022, GSNOR inhibitor N6022, N-6022, N 6022, GSNOR Inhibitor N-6022, CAS 1208315-24-5, GSNORi N6022), 10mM (in 1mL DMSO), CAS: 1208315-24-5.
N6022 (CAS 1208315-24-5) is a selective reversible inhibitor of S-nitrosoglutathione reductase (GSNOR) an enzyme involved in regulating the levels of S-nitrosoglutathione (GSNO) Inhibition of GSNOR leads to elevated GSNO concentrations promoting vasodilatory and anti-inflammatory effects In biochemical assays N6022 exhibits IC50 values of 8 nM (GSNO reduction assay) and 32 nM (HMGSH oxidation assay) with corresponding Ki values of 2 5 nM and 3 1 nM respectively Due to its selectivity profile and potency N6022 has entered clinical evaluation for inflammatory pulmonary conditions
Supply Solutions Dimethyl sulfoxide, 67-68-5, MFCD00002089, 100mL
Linear Formula (CH3)2SO, Molecular Weight 78.13, bp 189 C (lit.), mp 16-19 C (lit.), for molecular biology, Synonym: DMSO
Apexbio Technology LLC Doxercalciferol 54573-75-0 10mM (in 1mL DMSO)
Doxercalciferol chemically known as 1 -Hydroxyvitamin D2 is a synthetic analog of vitamin D2 characterized by selective activation of the vitamin D receptor (VDR) Upon metabolic activation Doxercalciferol undergoes hepatic transformation to its biologically active form inducing gene transcription mediated via the VDR signaling pathway Central to its mechanism activated VDR regulates calcium and phosphate homeostasis influencing cellular differentiation proliferation and parathyroid hormone expression In biomedical research Doxercalciferol serves as a tool compound to investigate the molecular pathways regulated by vitamin D receptor activation particularly in renal insufficiency models bone metabolism studies and parathyroid physiology experiments
Apexbio Technology LLC PP 2 (AG 1879) 172889-27-9 10mM (in 1mL DMSO)
PP 2 (AG 1879 CAS 172889-27-9) is a selective inhibitor targeting Src family tyrosine kinases such as Lck and Fyn with reported IC50 values of approximately 4 nM and 5 nM respectively Src family kinases are composed of nine closely related tyrosine kinases including Src Yes Fyn Fgr Yrk Lyn Blk Hck and Lck PP 2 suppresses early T-cell signaling by blocking Lck- and Fyn-mediated tyrosine phosphorylation following anti-CD3 stimulation Research in glioma cell models (U251) has demonstrated PP 2-mediated inhibition of Src-dependent cellular invasion and proliferation at micromolar concentrations PP 2 exhibits moderate inhibitory activity toward EGF-R (IC50 480 nM) and minimal effect on ZAP-70 and JAK2 Thus PP 2 serves as a research tool for studying Src kinase-dependent signaling pathways implicated in cancer and immunological responses
Apexbio Technology LLC Golvatinib (E7050) 928037-13-2 10mM (in 1mL DMSO)
Golvatinib (E7050 CAS 928037-13-2) is a small-molecule inhibitor targeting the tyrosine kinases c-Met and VEGFR-2 Golvatinib inhibits phosphorylation of c-Met in MKN45 gastric cancer cells and VEGFR-2 in human umbilical vein endothelial cells (HUVECs) with IC50 values of 14 nM and 16 nM respectively Additionally it suppresses proliferation of various tumor cells including MKN45 EBC-1 Hs746T and SNU-5 and inhibits tumor growth in xenograft models via reduction of c-Met and VEGFR-2-mediated pathways Golvatinib is utilized in cancer research to explore targeted antitumor efficacy related to angiogenesis and oncogenic signaling
Apexbio Technology LLC BLZ945 953769-46-5 10mM (in 1mL DMSO)
BLZ945 (CAS 953769-46-5) is a selective small-molecule inhibitor targeting colony-stimulating factor 1 receptor (CSF-1R) a receptor tyrosine kinase critical for macrophage and osteoclast differentiation proliferation migration and survival in response to macrophage colony-stimulating factor (M-CSF) BLZ945 inhibits CSF-1R kinase activity with an IC50 of 1 2 nM and reduces proliferation of M-CSF-dependent cells in vitro (e g EC50 of 71 M in MNFS-60 cells) In murine tumor models CSF-1R inhibition by BLZ945 reduces tumor-associated macrophage turnover and delays progression of breast and cervical tumors highlighting its utility in cancer and immune research
Apexbio Technology LLC BML-210(CAY10433) 537034-17-6 10mM (in 1mL DMSO)
BML-210 (CAY10433 CAS 537034-17-6) is a small molecule inhibitor targeting histone deacetylases (HDACs) enzymes responsible for removing acetyl groups from lysine residues on histone proteins leading to chromatin compaction and transcriptional repression BML-210 demonstrates HDAC inhibitory activity with an IC50 of 87 M In cellular assays this compound increases FXN mRNA expression and histone H4 acetylation induces G1 cell cycle arrest and apoptosis and enhances erythroid and granulocytic differentiation in human leukemia cell lines (K562 HL-60) BML-210 is utilized in research investigating epigenetic modulation leukemia biology and gene regulation mechanisms
Apexbio Technology LLC Regadenoson 313348-27-5 10mM (in 1mL DMSO)
Regadenoson is a selective low-affinity agonist targeting the adenosine A2A receptor a G protein-coupled receptor involved in vasodilation mechanisms By activating A2A receptors regadenoson induces coronary vasodilation through increased coronary blood flow (CBF) Prior in vitro binding experiments show that regadenoson displays high specificity towards the A2A subtype without significant interaction with adenosine receptor subtypes A1 A2B or A3 In animal models intravenous regadenoson administration elevates coronary artery blood flow transiently in a dose-dependent manner with minimal systemic hemodynamic changes Clinically regadenoson induces rapid increases in human coronary blood flow velocity making it suitable for diagnostic research applications related to coronary function